

Sosei Heptares partners InveniAl to launch multi-target Al-powered drug discovery platform

06 July 2021 | News

Creating transformative therapeutics for immune diseases by combining InveniAl's validated Al-based platform, AlphaMeld®, with Sosei Heptares' GPCR structure-based drug design and early development capabilities

Japan headquartered Sosei Group Corporation, the world leader in GPCR-focused structure-based drug design and development, and US-based InveniAl® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, have announced the initiation of a new R&D collaboration.

The objective of the collaboration is to identify new therapeutic product concepts for immune diseases where an AI and ML based approach can be applied to generate compelling evidence for the role of G-protein coupled receptors (GPCRs) in relevant immunomodulatory pathways; the goal being to use these targets as a basis for SBDD to generate novel compounds that could improve responses to existing immunotherapies.

The collaboration will combine InveniAl's Al-powered platform for target discovery with Sosei Heptares' world-leading GPCR structure-based drug design and early development capabilities generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.